SNGX

Soligenix Inc

0.3559

Oct 30 • 3:59 PM ET -0.0134 (-3.63%)

0.3481

Aftermarket • 7:56 PM ET -0.0078 (-2.19%)

Healthcare Biotechnology USA Nano NASD

Peers: CTXR VRCA AIM GOVX DRMA EDSA CUVL ACRS NNVC TLSA

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	7.75M
Enterprise Value	-1.76M
Income	-10.24M
Sales	0.00M
Book/sh	0.31
Cash/sh	0.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Apr 04, 1994

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.16
P/C	0.79
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.77
Current Ratio	2.77
Debt/Eq	0.05
LT Debt/Eq	0.03
Option/Short	No / Yes

EPS (ttm)	-1.27
EPS next Y	-0.25
EPS next Q	-0.10
EPS this Y	81.31%
EPS next Y	37.50%
EPS next 5Y	-
EPS past 3/5Y	69.72% 57.52%
Sales past 3/5Y	- -
EPS Y/Y TTM	66.94%
Sales Y/Y TTM	-
EPS Q/Q	84.88%
Sales Q/Q	-
Earnings	Aug 07 BMO
EPS/Sales Surpr.	22.58% -

Insider Own	4.59%
Insider Trans	0.00%
Inst Own	4.29%
Inst Trans	8.08%
ROA	-125.95%
ROE	-241.65%
ROIC	-149.97%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.15%
SMA50	-3.29%
SMA200	-47.72%
Trades

Shs Outstand	21.64M
Shs Float	20.77M
Short Float	0.78%
Short Ratio	0.82
Short Interest	0.16M
52W High	1.70 -79.00%
52W Low	0.28 27.11%
Volatility	7.57% 6.04%
ATR (14)	0.02
RSI (14)	47.67
Beta	2.06
Rel Volume	0.35
Avg Volume	199.79K
Volume	69,705

Perf Week	-2.49%
Perf Month	-2.17%
Perf Quarter	-5.72%
Perf Half Y	3.16%
Perf YTD	-73.44%
Perf Year	-76.43%
Perf 3Y	-95.59%
Perf 5Y	-99.85%
Perf 10Y	-99.97%
Recom	1.00
Target Price	1.50
Prev Close	0.37
Price	0.36
Change %	-3.63%

Consensus

Strong Buy

Avg. Price Target

$1.50

Implied Upside

+321.5%

Analysts3incl. previous ratings

Rating Distribution1 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 28, 2020	Downgrade	DDawson James	Buy → Neutral
Jan 31, 2018	Downgrade	HH.C. Wainwright	Buy → Neutral	$5.50 → $2.70	+658.6%
Aug 14, 2017	Reiterated	MMaxim Group	Buy	$4 → $5	+1,304.9%
Jul 17, 2017	Initiated	HH.C. Wainwright	Buy	$11	+2,990.8%

Aug-10-26 07:09AM	Soligenix culls topical lymphoma asset after Phase III miss (Clinical Trials Arena)
Aug-07-26 07:30AM	Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results (PR Newswire)
Jun-26-26 07:00AM	From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak (Newsfile)
Jun-08-26 07:30AM	Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine (PR Newswire)
May-27-26 07:28AM	SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month Ebola Vaccine Optimism Fuels Retail Frenzy (Stocktwits) +68.75%
07:30AM	Loading…
May-26-26 07:30AM	Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo (PR Newswire) +31.50%
May-08-26 07:30AM	Soligenix Announces Recent Updates and First Quarter 2026 Financial Results (PR Newswire)
Apr-28-26 11:06AM	SNGX Phase 3 Trial Halted on HyBryte (InvestorsHub) -70.25%
11:06AM	SNGX Phase 3 Trial Halted HyBryte Setback Puts Strategy in Question (InvestorsHub)
07:30AM	Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Apr-21-26 03:00PM	Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach (NewMediaWire)
Apr-20-26 02:23PM	Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status (NewMediaWire) +10.40%
Apr-17-26 02:30PM	Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results (NewMediaWire) +6.84%
Apr-02-26 03:30PM	Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy (NewMediaWire)
07:30AM	Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy (PR Newswire)
03:00PM	Loading…
Apr-01-26 03:00PM	Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results (NewMediaWire)
Mar-31-26 07:30AM	Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results (PR Newswire) +6.31%
Mar-26-26 03:30PM	Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet Disease (NewMediaWire)
07:30AM	Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behcet's Disease (PR Newswire)
Mar-25-26 02:45PM	Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach (NewMediaWire)
Mar-24-26 03:30PM	Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting (NewMediaWire)
Mar-23-26 03:30PM	Soligenix (SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation (NewMediaWire)
07:30AM	HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 (PR Newswire)
Mar-19-26 03:30PM	Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication (NewMediaWire)
Mar-10-26 03:15PM	Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease (NewMediaWire)
07:30AM	Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency (PR Newswire)
Mar-06-26 12:00PM	Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach (NewMediaWire)
Feb-26-26 07:30AM	Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behcet's Disease (PR Newswire)
Feb-24-26 07:30AM	Soligenix to Present at BIO Investment & Growth Summit (PR Newswire)
Feb-12-26 07:30AM	Soligenix Details Recent Progress and Upcoming Milestones (PR Newswire)
07:30AM	Loading…
Dec-18-25 07:30AM	Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford) (PR Newswire)
Dec-17-25 07:30AM	Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis (PR Newswire) -19.08%
Dec-05-25 08:30AM	Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad (GlobeNewswire)
Dec-03-25 08:30AM	Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space (GlobeNewswire)
Nov-19-25 07:30AM	Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Nov-07-25 07:30AM	Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results (PR Newswire) +7.03%
Oct-14-25 07:30AM	Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire) -5.23%
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile) +10.37%
Oct-07-25 07:30AM	Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) +19.71%
Sep-30-25 07:30AM	Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire)
Sep-29-25 04:05PM	Soligenix Announces Closing of $7.5 Million Public Offering (PR Newswire) -7.50%
Sep-26-25 06:33AM	Soligenix Announces Pricing of $7.5 Million Public Offering (PR Newswire) -25.93%
Sep-23-25 07:30AM	Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor (PR Newswire) -16.31%
Sep-04-25 07:30AM	Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses (PR Newswire)
Sep-02-25 07:30AM	Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +78.42%
07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results (PR Newswire)
07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behcet's Disease after Reviewing Recent Phase 2 Clinical Study Results (PR Newswire)
Aug-14-25 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results (PR Newswire) +20.00%
Aug-08-25 08:30AM	NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer (GlobeNewswire) -11.85%
Aug-07-25 08:30AM	Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy (GlobeNewswire)
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire) +7.38%
Aug-05-25 08:30AM	Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space (GlobeNewswire)
Aug-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.50%
08:30AM	Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas (PR Newswire)
Jul-31-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +134.40%
09:00AM	Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial (Benzinga)
07:30AM	Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease (PR Newswire)
05:31AM	Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON (GlobeNewswire)
Jul-08-25 07:30AM	Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones (PR Newswire) +8.93%
Jul-01-25 07:30AM	Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions (PR Newswire) +7.63%
Jun-06-25 09:37AM	Soligenix Highlights Dr. Ellen Kims Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials (GlobeNewswire)
May-09-25 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results (PR Newswire)
Apr-14-25 07:30AM	Positive Outcome in 75% of CTCL Patients Treated with HyBryte for 18 Weeks (PR Newswire) -9.89%
Mar-25-25 08:30AM	IBN Initiates Coverage of Soligenix Inc. (GlobeNewswire)
07:30AM	Soligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 Variants (PR Newswire)
Mar-21-25 07:30AM	Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results (PR Newswire)
Mar-06-25 07:30AM	HyBryte Treatment Studies Presented at Two Medical Conferences in March (PR Newswire)
Feb-04-25 07:30AM	Soligenix to Present at BIO CEO & Investor Conference (PR Newswire)
Jan-16-25 07:30AM	Soligenix to Present at Upcoming Investor Conferences (PR Newswire)
Jan-14-25 07:30AM	HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma (PR Newswire) -15.97%
07:15AM	EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year (Benzinga)
Dec-17-24 10:24AM	Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial (Clinical Trials Arena)
07:35AM	Soligenix initiates confirmatory Phase 3 trial of HyBryte (TipRanks)
Dec-16-24 07:30AM	Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
07:15AM	EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer (Benzinga)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESSWIRE)
Dec-02-24 07:30AM	HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment (PR Newswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-19-24 07:30AM	Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire)
Nov-15-24 07:30AM	Soligenix to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Nov-14-24 07:15AM	Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels (Benzinga)
07:15AM	Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behet's Disease (PR Newswire)
Nov-08-24 07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results (PR Newswire)
Oct-29-24 07:30AM	Soligenix Announces Participation at the Spartan Capital Investor Conference (NewMediaWire)
Oct-24-24 07:30AM	Soligenix, Inc. to Present at the 2024 ThinkEquity Conference (GlobeNewswire)
Oct-22-24 07:30AM	Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin (PR Newswire)
Oct-16-24 07:30AM	Soligenix Invited to Present at Upcoming Investor Conferences (PR Newswire)
Oct-07-24 07:30AM	HyBryte Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference (PR Newswire) +9.30%
Oct-03-24 07:30AM	Soligenix Announces Partnership with Sterling Pharma Solutions (PR Newswire) -18.89%
Sep-20-24 09:00AM	Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Sep-16-24 07:30AM	Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 (PR Newswire)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Sep-03-24 07:30AM	Soligenix Receives European Patent for Improved Production of Synthetic Hypericin (PR Newswire) +8.86%
Aug-16-24 09:00AM	Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +13.77%
Aug-09-24 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 09:00AM	Strong Clinical Momentum for Soligenix's HyBryte in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone (GlobeNewswire)
Jul-31-24 09:53AM	7 Top Stocks Under $10: July 2024 Edition (InvestorPlace)
Jul-15-24 10:16AM	PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte Lighting the Way Towards Commercial Success with Promising FLASH Study Results (GlobeNewswire) -7.67%
Jul-10-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)

Show Previous News

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Chairman of the Board of DirectorsDr. Christopher J. Schaber Ph.D.

CGMAMr. Jonathan L. Guarino CPA

Senior VP & Chief Scientific OfficerDr. Oreola Donini Ph.D.

Senior VP of Project Management & Regulatory AffairsMr. Adam T. Rumage

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNGX

Soligenix Inc

Upgrade your Finviz experience